WebApr 14, 2024 · Versions Abstract Despite excellent responses to anti-CD19 chimeric antigen receptor (CAR)-T cell therapy in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), more than half of patients will relapse due to poor CAR-T persistence or CD19 antigen escape. WebApr 7, 2024 · Chimeric antigen receptor-engineered (CAR) T-cell therapy remains limited by significant toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). The optimal management of severe and/or refractory CRS/ICANS remains ill-defined.
Sensory specializations drive octopus and squid behaviour
WebAbstract Objective: To obtain a CRS-R index suitable for diagnosis of patients with disorders of consciousness (DOC) and compare it to other CRS-R based scores to evaluate its potential for clinics and research. Design: We evaluated the diagnostic accuracy of several CRS-R-based scores in 124 patients with DOC. WebApr 6, 2024 · blogs.loc.gov misty millward hammer
Anakinra for refractory CRS or ICANS after CAR T-cell therapy
WebSource: CRS, based on the 2024 and 2024 OASDI trustees report. In the 2024 report, the trustees project a date of 2033 for OASI trust fund reserve depletion. The DI trust fund is … WebBackground: Glucose concentrations are increased in nasal secretions in chronic rhinosinusitis (CRS). However, the glucose metabolism and its contribution to disease pathogenesis in CRS remain unexplored. Objectives: We sought to explore the glucose metabolism and its effect on the function of nasal epithelial cells in CRS with and without … WebJun 10, 2024 · No new safety signals were identified with longer follow-up of either dose cohort. 2 The most common adverse events (AEs) at the 405 µg/kg QW dose were cytokine release syndrome (CRS; 76.7 percent; 3.3 percent Grade 3/4), neutropenia (66.7 percent; 60 percent Grade 3/4), skin-related AEs (66.7 percent; all Grade 1/2), and dysgeusia … misty mints candy